Cantargia is a biopharmaceutical company focusing on the development of immunotherapy treatments for cancer and autoimmune diseases, utilizing novel monoclonal antibody technology.
2005
Sweden
11 - 50 employees
Biotechnology
$25M - 100M in revenue
Not profitable
CO2e per visit (g)
Industry benchmark